A Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Blosozumab Proposed Phase 3 Formulation in Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
Price : $35 *
At a glance
- Drugs Blosozumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.